Patrick Soon-Shiong

Patrick Soon-Shiong, M.D. is an internationally recognized surgeon, scientist, inventor, and philanthropist with over 500 patents issued worldwide and the author of more than 100 peer-reviewed scientific publications. He serves as the Executive Chairman of ImmunityBio, a company he founded in 2014. He also serves as Chairman and CEO of NantHealth (NASDAQ:NH), a transformational healthcare company converging biomolecular medicine and bioinformatics with deep learning AI. Dr. Soon-Shiong is also the Owner and Executive Chairman of the Los Angeles Times and The San Diego Union-Tribune. Dr. Soon-Shiong serves as Chairman of the Chan Soon-Shiong Family Foundation and of the Chan Soon-Shiong Institute of Molecular Medicine.

Since the 1990s Dr. Soon-Shiong founded and led global pharmaceutical companies, American Pharmaceutical Partners and Abraxis BioScience, the latter of which is where he developed Abraxane, the first protein nanoparticle drug for breast, lung, and pancreatic cancer. The drug has achieved blockbuster status with annual sales exceeding a billion dollars and has now been acquired by Bristol Myers Squib. Dr. Soon-Shiong’s contribution to the advancement in cancer treatment has been honored by the Smithsonian National Museum of American History where Abraxane is now permanently housed, by the Friends of the National Library of Medicine Science with the Distinguished Medical Science award and by the Vatican with the Pontifical Key Visionary Award.

He received his medical degree at the University of Witwatersrand, Johannesburg, South Africa and continued his training in surgery at the University of California Los Angeles where he performed the first West Coast pancreas transplant and the world’s first encapsulated islet cell transplant. He is an adjunct Professor of Surgery at UCLA and a visiting Professor at the Imperial College of London.